Natera (NASDAQ:NTRA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

Other equities analysts also recently issued research reports about the company. Cowen restated a “buy” rating and issued a $12.00 price objective on shares of Natera in a report on Thursday, December 21st. Morgan Stanley restated an “overweight” rating and issued a $16.00 price objective (up previously from $13.00) on shares of Natera in a report on Friday, October 6th. Canaccord Genuity restated a “buy” rating and issued a $15.00 price objective on shares of Natera in a report on Tuesday, November 14th. Finally, Robert W. Baird restated a “buy” rating on shares of Natera in a report on Tuesday, October 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $14.50.

Shares of Natera (NASDAQ NTRA) opened at $9.77 on Wednesday. The company has a quick ratio of 1.75, a current ratio of 1.85 and a debt-to-equity ratio of 2.43. The stock has a market cap of $526.40 and a P/E ratio of -4.02. Natera has a 52-week low of $7.35 and a 52-week high of $14.76.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The company had revenue of $56.66 million during the quarter, compared to analysts’ expectations of $55.31 million. Natera had a negative return on equity of 197.09% and a negative net margin of 62.34%. Natera’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period last year, the company earned ($0.50) earnings per share. research analysts anticipate that Natera will post -2.15 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN grew its holdings in Natera by 2.8% during the second quarter. Wells Fargo & Company MN now owns 18,031 shares of the medical research company’s stock valued at $195,000 after purchasing an additional 491 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Natera by 1.3% during the second quarter. Principal Financial Group Inc. now owns 112,687 shares of the medical research company’s stock valued at $1,224,000 after purchasing an additional 1,409 shares during the last quarter. Voya Investment Management LLC grew its holdings in Natera by 17.8% during the second quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock valued at $159,000 after purchasing an additional 2,212 shares during the last quarter. California State Teachers Retirement System grew its holdings in Natera by 8.2% during the second quarter. California State Teachers Retirement System now owns 55,589 shares of the medical research company’s stock valued at $604,000 after purchasing an additional 4,200 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Natera by 23.3% during the second quarter. The Manufacturers Life Insurance Company now owns 26,826 shares of the medical research company’s stock valued at $291,000 after purchasing an additional 5,073 shares during the last quarter. Institutional investors own 66.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Natera (NTRA) Upgraded to “Hold” by Zacks Investment Research” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/10/natera-ntra-upgraded-to-hold-by-zacks-investment-research.html.

Natera Company Profile

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.